JP7158723B2 - 耳疾患の処置における使用のための（＋）－アザセトロン - Google Patents

耳疾患の処置における使用のための（＋）－アザセトロン Download PDF

Info

Publication number
JP7158723B2
JP7158723B2 JP2018553953A JP2018553953A JP7158723B2 JP 7158723 B2 JP7158723 B2 JP 7158723B2 JP 2018553953 A JP2018553953 A JP 2018553953A JP 2018553953 A JP2018553953 A JP 2018553953A JP 7158723 B2 JP7158723 B2 JP 7158723B2
Authority
JP
Japan
Prior art keywords
azasetron
pharmaceutical composition
hearing loss
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018553953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513780A5 (https=
JP2019513780A (ja
Inventor
ディハフジェルド－ジョンセン，ジョナス
Original Assignee
センソリオン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センソリオン filed Critical センソリオン
Priority claimed from PCT/EP2017/059058 external-priority patent/WO2017178645A1/en
Publication of JP2019513780A publication Critical patent/JP2019513780A/ja
Publication of JP2019513780A5 publication Critical patent/JP2019513780A5/ja
Application granted granted Critical
Publication of JP7158723B2 publication Critical patent/JP7158723B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018553953A 2016-04-14 2017-04-14 耳疾患の処置における使用のための（＋）－アザセトロン Active JP7158723B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
US62/322,690 2016-04-14
EP16180192.3 2016-07-19
EP16180192 2016-07-19
PCT/EP2017/059058 WO2017178645A1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders

Publications (3)

Publication Number Publication Date
JP2019513780A JP2019513780A (ja) 2019-05-30
JP2019513780A5 JP2019513780A5 (https=) 2021-08-12
JP7158723B2 true JP7158723B2 (ja) 2022-10-24

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553953A Active JP7158723B2 (ja) 2016-04-14 2017-04-14 耳疾患の処置における使用のための（＋）－アザセトロン

Country Status (18)

Country Link
US (2) US11612605B2 (https=)
EP (1) EP4335508A3 (https=)
JP (1) JP7158723B2 (https=)
CN (1) CN109310698B (https=)
AU (1) AU2023202897B2 (https=)
CL (1) CL2018002930A1 (https=)
DK (1) DK3442537T3 (https=)
ES (1) ES2975016T3 (https=)
FI (1) FI3442537T3 (https=)
HR (1) HRP20240453T1 (https=)
HU (1) HUE066000T2 (https=)
IL (1) IL262305B (https=)
MX (1) MX384045B (https=)
NZ (1) NZ747201A (https=)
PL (1) PL3442537T3 (https=)
RS (1) RS65379B1 (https=)
SI (1) SI3442537T1 (https=)
ZA (1) ZA201806894B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847489B (zh) * 2015-05-18 2021-09-17 森索睿翁公司 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528036A (ja) 2008-07-14 2011-11-10 オトノミ―，インク． 制御放出アポトーシス調節化合物および耳の障害の処置のための方法
JP2012527430A (ja) 2009-05-20 2012-11-08 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬
JP2015524408A (ja) 2012-07-16 2015-08-24 コーネル ユニヴァーシティー 難聴を治療するためのニコチンアミドリボシド

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
WO2003071986A2 (en) 2002-02-22 2003-09-04 Control Delivery Systems, Inc. Method for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
JP2006516977A (ja) 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
ES2432618T3 (es) 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
WO2013124416A1 (en) 2012-02-23 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
BR112016002205A2 (pt) * 2013-07-31 2017-08-01 Bluepharma Ind Farmaceutica S A filmes orodispersíveis
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
CN107847489B (zh) 2015-05-18 2021-09-17 森索睿翁公司 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528036A (ja) 2008-07-14 2011-11-10 オトノミ―，インク． 制御放出アポトーシス調節化合物および耳の障害の処置のための方法
JP2012527430A (ja) 2009-05-20 2012-11-08 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬
JP2015524408A (ja) 2012-07-16 2015-08-24 コーネル ユニヴァーシティー 難聴を治療するためのニコチンアミドリボシド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Nature Reviews Drug Discovery，2002年，Vol.1，pp.753-768
Pharmac.Ther.，1990年，Vol.45，pp.309-329
YAKUGAKU ZASSHI，2008年，Vol.128，pp.649-655

Also Published As

Publication number Publication date
FI3442537T3 (fi) 2024-04-04
EP4335508A3 (en) 2024-07-10
IL262305B (en) 2022-03-01
PL3442537T3 (pl) 2024-07-15
AU2023202897B2 (en) 2025-01-30
US20190083503A1 (en) 2019-03-21
DK3442537T3 (da) 2024-03-25
SI3442537T1 (sl) 2024-05-31
ES2975016T3 (es) 2024-07-02
MX384045B (es) 2025-03-14
RS65379B1 (sr) 2024-04-30
US20230226071A1 (en) 2023-07-20
NZ747201A (en) 2023-02-24
CL2018002930A1 (es) 2019-02-15
AU2023202897A1 (en) 2023-05-25
IL262305A (en) 2018-11-29
HRP20240453T1 (hr) 2024-06-21
EP4335508A2 (en) 2024-03-13
CN109310698B (zh) 2021-12-24
ZA201806894B (en) 2023-03-29
US11612605B2 (en) 2023-03-28
JP2019513780A (ja) 2019-05-30
HUE066000T2 (hu) 2024-06-28
MX2018012587A (es) 2019-03-07
CN109310698A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
EP2203050B1 (en) Topical use of r(+)-n-propargyl-1-aminoindan to treat or prevent hearing loss
JP5612473B2 (ja) 難聴を処置又は予防するための１−アミノ−アルキルシクロヘキサン誘導体
EP3737233B1 (en) Growth factor otic formulations
KR102429935B1 (ko) 귀 장애의 치료에 사용하기 위한 (+)-아자세트론
EP3810146A1 (en) Otic formulations for drug-induced ototoxicity
KR20160047490A (ko) 소아 귀 질환의 치료
US20240066099A1 (en) Bdnf otic formulations and use thereof
US11110112B2 (en) Methods for the use of 5'-adenosine diphosphate ribose (ADPR)
AU2023202897B2 (en) (+)-Azasetron for use in the treatment of ear disorders
JP6271804B1 (ja) 耳炎の治療のための組成物および方法
US20230390273A1 (en) 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases
HK40106593A (en) (+)-azasetron for use in the treatment of ear disorders
WO2011049954A2 (en) Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders
WO2021127275A1 (en) Gsk-3 modulator otic formulations
BR112018071123B1 (pt) (+)-azasetron para uso no tratamento de distúrbios de ouvido
HK40003071B (en) (+)-azasetron for use in the treatment of ear disorders
HK40003071A (en) (+)-azasetron for use in the treatment of ear disorders
KR20240162447A (ko) 알파 리포산 (Alpha lipoic acid, ALA)을 유효성분으로 포함하는 난청 예방 또는 치료용 약학적 조성물
RU2452476C2 (ru) Производные 1-аминоалкилциклогексана для лечения и предупреждения потери слуха
Munguia CiprofloxacinDexamethasone ototoxicity in an animal and human model
WO2022140636A1 (en) Gacyclidine otic formulations and uses thereof
EP4251127A1 (en) Pharmaceutical composition for treatment of inner ear disorders through local administration in the tympanic area
HK1145419B (en) Topical use of r(+)-n-propargyl-1-aminoindan to treat or prevent hearing loss

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210625

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221004

R150 Certificate of patent or registration of utility model

Ref document number: 7158723

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250